Last updated August 21, 2026
Key finding
The changes from baseline to 12 months in CNFL did not differ between the two groups.
This study evaluated the efficacy and safety of benfotiamine in treating diabetic sensorimotor polyneuropathy. Results indicated no significant differences between benfotiamine and placebo groups.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the efficacy and safety of benfotiamine in treating diabetic sensorimotor polyneuropathy. Results indicated no significant differences between benfotiamine and placebo groups.
Understanding the effectiveness of treatments for diabetic neuropathy is crucial for managing this common complication of diabetes. This study suggests that benfotiamine may not provide additional benefits over placebo, guiding clinicians in treatment decisions and patient expectations.
The study may have lacked sufficient power to detect small differences. Findings may not be generalizable to all diabetic populations. The assessment methods for neuropathy symptoms may have limitations.
Published in
Publication details and source links for this paper.
Dan Z, Gundega S, Alexander S, et al. Efficacy and safety of benfotiamine in diabetic sensorimotor polyneuropathy: a randomized controlled trial. BMJ Open Diabetes Research & Care. 2026;14(1):e005773. doi:10.1136/bmjdrc-2025-005773
No significant change in corneal nerve fiber length (CNFL) between benfotiamine and placebo groups.
No significant difference in median nerve conduction velocity (MNCV) between the two groups.
Neuropathy Symptom Score showed a trend towards improvement with benfotiamine (p=0.098).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Benfotiamine 300 mg and Change in corneal nerve branch density (CNBD), Change in corneal nerve fiber density (CNFD), Change in corneal nerve fiber length (CNFL), and 3 more.
This study contributes evidence to
Primary intervention
Benfotiamine 300 mg
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
0
Related topics
6
Evidence pairs
0
Related studies
Core evidence
The primary outcomes reported in this study.
Benfotiamine 300 mg → Change in corneal nerve branch density (CNBD)
Benfotiamine 300 mg → Change in corneal nerve branch density (CNBD)
Benfotiamine 300 mg → Change in corneal nerve fiber density (CNFD)
Benfotiamine 300 mg → Change in corneal nerve fiber density (CNFD)
Benfotiamine 300 mg → Change in corneal nerve fiber length (CNFL)
Benfotiamine 300 mg → Change in corneal nerve fiber length (CNFL)
Benfotiamine 300 mg → Health-related quality of life
Benfotiamine 300 mg → Health-related quality of life
Benfotiamine 300 mg → median nerve conduction velocity (MNCV)
Benfotiamine 300 mg → median nerve conduction velocity (MNCV)
Benfotiamine 300 mg → Neuropathy symptom score
Benfotiamine 300 mg → Neuropathy symptom score
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Benfotiamine 300 mg and Change in corneal nerve branch density (CNBD), Benfotiamine 300 mg and Change in corneal nerve fiber density (CNFD).
This study contributes to the evidence on the following intervention-outcome relationships.
Curated evidence collections and hubs this study is part of.
All studies on Benfotiamine 300 mg
Contributes to Benfotiamine 300 mg evidence base.
All studies measuring Change in corneal nerve branch density (CNBD)
Measures Change in corneal nerve branch density (CNBD) as a key outcome.
All studies measuring Change in corneal nerve fiber density (CNFD)
Measures Change in corneal nerve fiber density (CNFD) as a key outcome.
All studies measuring Quality of Life Outcomes
Measures Quality of Life Outcomes as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Current evidence does not show a clear benefit of Benfotiamine 300 mg for Change in corneal nerve branch density (CNBD).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Change in corneal nerve branch density (CNBD)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Benfotiamine 300 mg for Change in corneal nerve fiber density (CNFD).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Change in corneal nerve fiber density (CNFD)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Benfotiamine 300 mg for Change in corneal nerve fiber length (CNFL).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Change in corneal nerve fiber length (CNFL)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Benfotiamine 300 mg for Health-related quality of life.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Health-related quality of life
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
